Posts

PEMBROLIZUMAB APPROVED FOR UROTHELIAL CANCER

0

IDO INHIBITOR READY FOR PRIME TIME

0

ANTI-CD27 IMMUNOTHERAPY READY FOR PRIME TIME

0

ADDING PERTUZUMAB TO HERCEPTIN-CAPECITABINE OF NO PFS BENEFIT

0

LETROZOLE-RIBOCICLIB CO-PACKAGE APPROVED BY FDA

0

GENE FOUND IMPLICATED IN HEARING LOSS BY CISPLATIN

0

PEMBROLIZUMAB APPROVED IN COMBINATION WITH CHEMOTHERAPY FOR NON-SQUAMOUS NSCLC

0

PEMBROLIZUMAB APPROVED BY EMA FOR HODGKIN LYMPHOMA

0

LOCAL CHEMOTHERAPY AFTER METASTATECTOMY FOR COLORECTAL CANCER

0

WHY ONCOLOGISTS PRESCRIBE PRE-DEATH CHEMOTHERAPY?

0

NEW AND SAFER CHEMOTHERAPY TRANSFER DEVICE

0

EVEROLIMUS FOR TUBEROUS SCLEROSIS

0

HIGH RISK OF THROMBOSIS IN OVARIAN CANCER

0

NEW STANDARD OF CARE FOR EGFR+ NSCLC

0

NO BENEFIT OF ADJUVANT GEMCITABINE IN BREAST CANCER

0

NEW STAGING SYSTEM FOR THYROID CANCER

0